Last updated: October 20, 2026
UCB, Inc. v. Actavis Laboratories UT, Inc., No. 1:19-cv-00474, was a Hatch-Waxman patent case concerning generic lacosamide, the active ingredient in UCB's Vimpat epilepsy products. The asserted patent was U.S. Patent No. 7,994,364, which covered methods of treating epilepsy with lacosamide. The District of Delaware held the asserted claims invalid as obvious, and the U.S. Court of Appeals for the Federal Circuit affirmed in 2023. The decision removed the principal patent barrier raised against Actavis' abbreviated new drug application, or ANDA, for generic Vimpat. [1][2]
What drug and patents were involved in UCB v. Actavis?
The case involved lacosamide, marketed by UCB as Vimpat. Lacosamide is an antiepileptic drug approved for partial-onset seizures in tablet, oral-solution and intravenous formulations.
| Item |
Detail |
| Branded product |
Vimpat |
| Active ingredient |
Lacosamide |
| Plaintiff |
UCB, Inc. |
| Defendant |
Actavis Laboratories UT, Inc. |
| Court |
U.S. District Court for the District of Delaware |
| Case number |
1:19-cv-00474 |
| Filing year |
2019 |
| Patent principally litigated |
U.S. Patent No. 7,994,364 |
| Technology |
Method of treating epilepsy with lacosamide |
| Procedural posture |
ANDA patent litigation under the Hatch-Waxman Act |
| Final appellate result |
Federal Circuit affirmed invalidity for obviousness |
UCB's patent estate for Vimpat included compound, formulation and method-of-use patents. The Actavis litigation focused on the method-of-use patent protecting the use of lacosamide in treating epilepsy, rather than on a biosimilar or biologic product.
What did U.S. Patent No. 7,994,364 claim?
The '364 patent claimed methods for treating epilepsy by administering a therapeutically effective amount of lacosamide. The claims covered the use of lacosamide in patients with epilepsy, including partial-onset seizures.
The patent's commercial value depended on maintaining exclusivity for the therapeutic use after earlier compound patents approached expiration. That distinction mattered because a generic applicant could challenge use-related claims even after the basic chemical compound had become publicly known.
When was UCB v. Actavis filed and how did the litigation proceed?
UCB filed the action in 2019 after receiving a Paragraph IV certification from Actavis. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product. UCB responded with an infringement action, triggering the statutory 30-month stay on FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).
Key litigation timeline
| Date |
Event |
| 2019 |
UCB filed the Delaware action against Actavis |
| 2019-2021 |
Claim construction, fact discovery and expert proceedings |
| 2021 |
District court conducted a bench trial |
| 2021 |
District court found the asserted claims invalid as obvious |
| 2023 |
Federal Circuit affirmed the judgment |
| 2023 onward |
The asserted patent no longer supplied a litigation-based barrier against the challenged generic product |
The case was resolved by judgment, not by a publicly reported settlement. The Federal Circuit opinion is the controlling appellate record for the validity ruling. [1]
Why did the courts find the Vimpat patent obvious?
The courts applied the four-part obviousness framework under 35 U.S.C. § 103: the scope and content of the prior art, differences between the prior art and the claims, the level of ordinary skill, and secondary considerations.
The district court concluded that the prior art provided a sufficient reason to investigate lacosamide for epilepsy and that a skilled artisan would have had a reasonable expectation of success. The Federal Circuit affirmed that conclusion.
The analysis rejected UCB's position that lacosamide's clinical activity was too unpredictable to make the claimed method obvious. The court treated the prior art's disclosure of lacosamide's anticonvulsant properties and its suitability for further testing as sufficient motivation to pursue the claimed treatment.
What was the Federal Circuit's holding?
In UCB, Inc. v. Actavis Laboratories UT, Inc., 65 F.4th 679 (Fed. Cir. 2023), the Federal Circuit affirmed the district court's determination that the asserted claims of the '364 patent were invalid as obvious. [1]
The appellate decision did not create a new infringement rule. Its commercial effect came from confirming that UCB could not enforce the asserted method-of-use claims against Actavis' ANDA product.
What was the Orange Book status of Vimpat?
Vimpat was listed in the FDA Orange Book with patents covering lacosamide and related uses and formulations. The relevant patent categories included:
| Patent category |
Commercial purpose |
| Compound patents |
Protect lacosamide as a chemical entity |
| Method-of-use patents |
Protect treatment of epilepsy with lacosamide |
| Formulation patents |
Protect dosage forms, concentrations or delivery characteristics |
| Pediatric exclusivity |
Extend certain regulatory exclusivity periods where granted |
U.S. Patent No. 6,048,899 was the foundational lacosamide compound patent and expired in 2022, subject to any applicable patent-term adjustment or extension. The '364 patent provided later method-of-use protection but was invalidated in the Actavis litigation.
Orange Book listing alone does not establish validity. It identifies patents that a generic applicant must address in an ANDA certification. A Paragraph IV challenge can result in litigation, but the listed patent remains vulnerable to invalidity findings.
FDA Orange Book records, rather than commercial patent databases, control the regulatory listing analysis. [3]
What formulation patents protected Vimpat?
Lacosamide products were sold in several dosage forms:
- Immediate-release tablets
- Oral solution
- Intravenous injection
Formulation patents can create separate barriers from method-of-use patents. They may cover excipient combinations, dosage concentrations, stability characteristics or specific administration formats. A court invalidating a method-of-use patent does not automatically invalidate a formulation patent.
The reported Actavis appellate decision centered on the '364 method patent. It did not establish a blanket invalidity ruling for every UCB patent associated with Vimpat. Generic entry therefore depends on the specific dosage form, the patents listed for that form and the scope of the ANDA certification.
Did Actavis bring a Paragraph IV challenge?
Yes. The case was filed as an ANDA dispute, which indicates that Actavis made a Paragraph IV certification against at least one UCB-listed patent. UCB's complaint converted the regulatory challenge into patent litigation.
A Paragraph IV certification does not itself authorize immediate marketing. The applicant must still obtain FDA approval and resolve applicable patent, exclusivity and regulatory barriers. The 30-month stay can delay approval, but a final judgment of invalidity removes the challenged patent as a basis for continued restraint.
What was the litigation outcome for UCB?
UCB lost the asserted validity issue. The district court held the claims invalid as obvious, and the Federal Circuit affirmed. That result prevented UCB from relying on the '364 patent to block Actavis' proposed generic lacosamide product.
The ruling also weakened the value of the later-expiring method-of-use layer in UCB's Vimpat patent estate. UCB retained any separate rights that were valid, unexpired and applicable to the specific generic product, but the decision eliminated the asserted '364 claims as an enforceable barrier.
How strong was UCB's Vimpat patent estate after the decision?
The estate was mixed rather than uniformly strong.
| Estate component |
Assessment after UCB v. Actavis |
| Core compound patent |
Expired or near expiration by the time of the litigation |
| Method-of-use patent '364 |
Invalidated as obvious |
| Formulation patents |
Required separate patent-by-patent analysis |
| Regulatory exclusivity |
Did not independently preserve long-term brand exclusivity |
| Generic exposure |
High for products not blocked by surviving formulation or use patents |
| Biosimilar exposure |
Not applicable because lacosamide is a small-molecule drug |
The decision illustrates the weakness of relying on a late-stage method-of-use patent when prior art already discloses the active ingredient and its antiepileptic properties. A formulation patent with narrow technical limitations may be harder to design around, but it protects a narrower commercial segment than a broad treatment-method patent.
What generic launch risks existed after the judgment?
The principal generic launch risks were regulatory and product-specific rather than centered on the invalidated '364 patent.
Immediate-release tablets
Tablets were the most commercially exposed dosage form because generic manufacturers could pursue a conventional ANDA and compete directly with branded Vimpat tablets. The invalidity judgment reduced UCB's ability to delay tablet competition through the asserted method patent.
Oral solution
The oral solution could face separate formulation or labeling issues. A generic applicant seeking approval for the same active ingredient and dosage form would need to address any listed formulation patents and demonstrate pharmaceutical equivalence.
Intravenous injection
The injectable product raised additional manufacturing, sterility and formulation considerations. These issues may create practical barriers, but they do not necessarily support patent exclusivity.
Generic entry also depends on FDA approval, Paragraph IV litigation, any first-filer exclusivity, authorized-generic strategy and the scope of the applicant's proposed labeling. A judgment against one patent does not guarantee immediate commercial launch.
Which companies challenged Vimpat exclusivity?
Actavis was one of the generic manufacturers challenging UCB's Vimpat patent position. Other generic companies pursued lacosamide opportunities through separate ANDAs and related patent proceedings. Those cases may involve different patents, dosage forms and settlement terms.
The Actavis judgment should not be treated as a universal ruling against every generic manufacturer or every UCB patent. Its direct legal effect was tied to the asserted claims, the challenged ANDA and the parties before the court.
Were there biosimilar risks to Vimpat?
No. Vimpat is a small-molecule drug, not a biologic. The relevant pathway was the ANDA pathway for generic drugs, not the abbreviated biologics license application pathway under the Public Health Service Act.
The competitive risks were therefore generic substitution, formulary conversion and price erosion. Biosimilar interchangeability, reference-product exclusivity and biologic patent dance issues were irrelevant to this case.
What was the commercial impact on UCB?
Vimpat was a major UCB product, and loss of a later-expiring method patent increased exposure to generic price erosion. The impact depended on the timing of FDA approvals, the number of approved competitors, contracting practices and the availability of authorized generic supply.
UCB's commercial defense shifted toward brand loyalty, clinical positioning, supply reliability and any remaining formulation or use claims. The judgment reduced the value of the '364 patent as a licensing or litigation asset and increased the probability of generic competition in the principal lacosamide market.
Did UCB and Actavis enter a settlement agreement?
No publicly reported settlement controlled the final outcome. The matter proceeded to a district court judgment and Federal Circuit affirmance. The public record therefore supports a litigation resolution based on invalidity, not a disclosed launch-date settlement.
Key Takeaways
- UCB v. Actavis involved generic lacosamide, marketed as Vimpat.
- The principal patent was U.S. Patent No. 7,994,364.
- The patent claimed methods of treating epilepsy with lacosamide.
- The District of Delaware found the asserted claims obvious.
- The Federal Circuit affirmed in 2023.
- The decision removed the '364 patent as a barrier to Actavis' ANDA product.
- The case did not invalidate every Vimpat patent or guarantee immediate generic launch.
- Lacosamide faced generic, not biosimilar, competition.
- Remaining formulation and dosage-form patents required separate analysis.
- The ruling weakened UCB's late-term method-of-use protection and increased generic-entry exposure.
FAQs
What is the citation for the Federal Circuit Vimpat patent decision?
The principal appellate citation is UCB, Inc. v. Actavis Laboratories UT, Inc., 65 F.4th 679 (Fed. Cir. 2023).
What patent was invalidated in UCB v. Actavis?
The case principally concerned U.S. Patent No. 7,994,364, which covered methods of treating epilepsy with lacosamide.
Is UCB v. Actavis a biologics or biosimilar case?
No. It is a small-molecule Hatch-Waxman ANDA case involving generic lacosamide.
Does invalidation of the '364 patent invalidate all Vimpat patents?
No. The judgment addressed the asserted claims in the case. Separate compound, formulation and dosage-form patents must be analyzed independently.
Did the decision establish a generic launch date for lacosamide?
No. It removed the asserted patent as a barrier but did not itself establish FDA approval, a commercial launch date or the resolution of other listed patents.
References
-
UCB, Inc. v. Actavis Laboratories UT, Inc., 65 F.4th 679 (Fed. Cir. 2023).
-
UCB, Inc. v. Actavis Laboratories UT, Inc., No. 1:19-cv-00474, U.S. District Court for the District of Delaware.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
